Editorial: DNA polymerase and hepatitis B antigen.
D002353:Carrier State / Q000276:immunology; D004254:DNA Nucleotidyltransferases / Q000032:analysis* / Q000037:antagonists & inhibitors; D003609:Dactinomycin / Q000494:pharmacology; D003630:Daunorubicin / Q000494:pharmacology; D006506:Hepatitis A / Q000201:enzymology / Q000276:immunology; D006511:Hepatitis B Antigens / Q000032:analysis*; D006801:Humans; D007181:Inclusion Bodies, Viral; D012194:RNA-Directed DNA Polymerase / Q000032:analysis; D012293:Rifampin / Q000494:pharmacology
D006511:Hepatitis B Antigens; D003609:Dactinomycin; D004254:DNA Nucleotidyltransferases; D012194:RNA-Directed DNA Polymerase; D012293:Rifampin; D003630:Daunorubicin